AZD9833
oral selective ER degrader and antagonist in Ph. IIb studies for ER+ breast cancer from ligand-based design and opt. J. Med. Chem., Sep. 29, 2020 AstraZeneca, Cambridge, UK / Waltham, MA
Molecules of the Month - September 2020
Molecules of the Month
- FGF401 (roblitinib)
- TNO155
- BMS-986143
- AZD9833
- AL-611
- PF-06882961
- PF-05221304
- PF-06835919
- "compound 9"
- GLPG1205
- OP-5244
- SCO-267
- "compound 23"
- TAS-120 (futibatinib)